Thrombocytopenia in Pregnancy: A Diagnostic Approach
Clinical Practice Update — How ACOG Practice Bulletin 207, ASH guidance and ASH Education Program reviews, pregnancy-specific platelet reference data and the SOAP neuraxial consensus shape the workup of a low platelet count in pregnancy
This is an original clinical education article informed by current guidelines and evidence. See References below for source documents.
- Clinical Focus
- Confirming true thrombocytopenia, reading trimester of onset and severity, the first-line laboratory workup, separating preeclampsia and HELLP from TTP and complement-mediated TMA, distinguishing gestational thrombocytopenia from ITP, ITP treatment thresholds, platelet targets for birth and neuraxial anaesthesia, special populations, and maternal and neonatal follow-up
- Target Audience
- Obstetricians, maternal-fetal medicine specialists, haematologists, obstetric anaesthesiologists, family physicians, midwives, obstetric nurses, residents and medical students
- Setting
- Antenatal clinics, obstetric triage, labour and delivery units, haematology clinics, postpartum wards and neonatal units
- Source Evidence
- •ACOG Practice Bulletin No. 207: Thrombocytopenia in Pregnancy (Obstet Gynecol, 2019)
- •ASH Clinical Practice Guide on Thrombocytopenia in Pregnancy (American Society of Hematology, 2013)
- •ASH Education Program: Thrombocytopenia in Pregnancy (Pishko and Marshall, 2022)
- •ASH Education Program: A Practical Approach to Immune Thrombocytopenia in Pregnancy (Matusiak, Malinowski and Arnold, 2025)
- •Updated International Consensus Report on Primary Immune Thrombocytopenia (Blood Adv, 2019)
- •SOAP Interdisciplinary Consensus Statement on Neuraxial Procedures in Thrombocytopenia (Anesth Analg, 2021)
- •Platelet Counts During Pregnancy (Reese et al, N Engl J Med, 2018)
- •International Working Group Report on Thrombotic Microangiopathy in Pregnancy and Postpartum (Blood, 2020)
What Changed in Practice
Thrombocytopenia in pregnancy — a platelet count below 150 × 10⁹/L (equivalent to 150 × 10³/µL) — affects 7–12% of pregnancies by delivery, and most cases are benign.1 The clinical skill lies in separating a physiological dip from disorders that threaten the mother or baby, and current ACOG and ASH-affiliated guidance has sharpened that diagnostic workup.1,3,4
Key Clinical Takeaways
Direct actions for thrombocytopenia in pregnancy, most practice-changing first.
- 1Investigate for a cause other than gestational thrombocytopenia whenever the count is below 100 × 10⁹/L, or below 150 × 10⁹/L in the first trimester → What Do Timing and Severity Tell You?
- 2Check blood pressure, urine protein, liver enzymes, LDH and creatinine in every patient with new thrombocytopenia after 20 weeks → Could This Be a Thrombotic Microangiopathy?
- 3Draw ADAMTS13 and call haematology the same day for thrombocytopenia with schistocytes plus neurological signs, severe kidney injury, onset before 20 weeks or failure to improve after birth → Could This Be a Thrombotic Microangiopathy?
- 4Confirm any unexpected low count with a blood film before labelling it, to exclude platelet clumping → Is the Low Platelet Count Real?
- 5Treat ITP when there is bleeding or the count falls below 30 × 10⁹/L, and plan to reach 50 × 10⁹/L for cesarean and a stable 70 × 10⁹/L for neuraxial anaesthesia → When Does ITP in Pregnancy Need Treatment?
- 6Decide the mode of birth on obstetric grounds and avoid fetal platelet sampling → What Platelet Count Is Enough for Birth?
- 7Arrange a neonatal platelet count at birth and over the first days of life when the mother has ITP → Monitoring and Follow-Up of Thrombocytopenia in Pregnancy
Why This Update Matters
Gestational thrombocytopenia accounts for 70–80% of thrombocytopenia in pregnancy and carries no maternal or fetal risk.7 The danger lies in the minority: preeclampsia with severe features, HELLP syndrome, TTP and complement-mediated TMA can progress within hours, and untreated ITP can leave a mother without neuraxial options at term.3,6 Over-investigating the majority causes anxiety; under-investigating the minority delays time-critical care.
Is the Low Platelet Count Real?
The first step in any thrombocytopenia in pregnancy workup is confirming that the number is true and isolated. The initial assessment pairs a blood film with renal and hepatic function, a targeted history and a focused examination.3,4
Perform a repeat complete blood count with a peripheral blood film for every new, unexpected low platelet count before assigning a diagnosis.
Strong RecLow EvidenceASH Educ 2022ASH Educ 2025Repeat the count in a citrate tube when the film shows platelet clumping, since EDTA-dependent pseudothrombocytopenia needs no further workup.
Moderate RecLow EvidenceASH Educ 2022Review medications, earlier pregnancy counts and any personal or family history of bleeding, then examine for hypertension, bruising, hepatosplenomegaly and lymphadenopathy.
Strong RecLow EvidenceASH Educ 2022Cines 2017Evaluate the other cell lines: mild dilutional or iron-deficiency anaemia is common and may be unrelated, but pancytopenia warrants haematology review and consideration of bone marrow examination when no drug or vitamin cause is found.
Strong RecLow EvidenceASH Educ 2022Compare with the booking or pre-pregnancy count to establish the trajectory. Practice impact: request the earlier result before ordering a broad panel.
Moderate RecLow EvidenceASH Educ 2025What Do Timing and Severity Tell You?
Reading thrombocytopenia in pregnancy starts with the normal trajectory: platelet counts fall gradually across pregnancy, and the delivery distribution is shifted to the left of the non-pregnant range.2,4 The proportion of uncomplicated pregnancies below 150 × 10⁹/L rises from 1.8% in the first trimester to 4.8% in the second and 8.5% in the third.2 Hypertensive disorders appear after 20 weeks, most after 34 weeks.3
Reading Thrombocytopenia in Pregnancy by Timing and Depth
This grid is Medaptly’s synthesis of ACOG PB 207, ASH guidance and Reese 2018; it supports, but does not replace, clinical assessment.
| Presentation | Most Likely Explanation | Must Not Miss | First Move |
|---|---|---|---|
| 100–149 × 10⁹/L, well, second or third trimester, normal blood pressure | Gestational thrombocytopenia | Evolving preeclampsia | Routine care; check blood pressure at each visit |
| Below 150 × 10⁹/L in the first trimester | ITP or inherited thrombocytopenia | Type 2B VWD, HIV or HCV, marrow disorder | ITP workup; haematology if below 100 or falling |
| Below 100 × 10⁹/L at any gestation | ITP; hypertensive disorder after 20 weeks | HELLP syndrome, TTP | Full workup the same week, or same day if unwell |
| Below 50 × 10⁹/L | ITP (rarely gestational) | TTP, DIC, marrow failure | Urgent haematology input |
| New fall after 20 weeks with hypertension or upper abdominal pain | Preeclampsia with severe features or HELLP | Acute fatty liver, TTP | Same-day obstetric assessment and HELLP panel |
| Sudden peripartum fall with bleeding | DIC from abruption, haemorrhage, embolism or sepsis | Dilutional coagulopathy | Fibrinogen and coagulation studies now |
| Fall of 50% or more 5–14 days after starting heparin | Heparin-induced thrombocytopenia | Thrombosis | Pretest probability and HIT testing |
Attribute a count of 100–149 × 10⁹/L to gestational thrombocytopenia in asymptomatic women with no bleeding history, provided blood pressure and other results are normal.
Strong RecModerate EvidenceACOG PB 207Reese 2018Evaluate for an alternative cause when the count is below 100 × 10⁹/L at any gestation. Practice impact: stop writing “gestational” beside counts in this range until a workup is done.
Moderate RecModerate EvidenceACOG PB 207Reese 2018Consider gestational thrombocytopenia unlikely below 70 × 10⁹/L.
Moderate RecLow EvidenceASH 2013Evaluate for ITP or an inherited disorder when thrombocytopenia in pregnancy begins in the first trimester.
Strong RecLow EvidenceASH Educ 2022Which Tests Belong in a Thrombocytopenia in Pregnancy Workup?
The workup for thrombocytopenia in pregnancy should widen in proportion to severity and context. A platelet count below 100 × 10⁹/L is itself a severe feature of preeclampsia, so blood pressure and organ-function testing come first after 20 weeks.10
Tests, Targets and Consequences
| Test | Who Needs It | What an Abnormal Result Changes |
|---|---|---|
| Repeat blood count with film | Everyone | Confirms the count; shows clumping, schistocytes, large platelets or blasts |
| Blood pressure, urine protein-to-creatinine ratio | Everyone after 20 weeks | Moves the diagnosis toward the preeclampsia spectrum |
| AST, ALT, LDH, bilirubin, creatinine | After 20 weeks, or any count below 100 × 10⁹/L | Identifies haemolysis, liver injury or kidney injury |
| PT, aPTT, fibrinogen | Count below 100 × 10⁹/L, bleeding, liver dysfunction, suspected abruption | Points to DIC or acute fatty liver; informs anaesthesia |
| HIV, hepatitis C, hepatitis B | Suspected ITP | Identifies secondary ITP and changes treatment |
| Reticulocyte count | Suspected ITP or anaemia | Separates production from destruction |
| Antiphospholipid antibodies, ANA, thyroid tests, H. pylori | Only when clinically indicated | Identifies secondary causes |
| ADAMTS13 activity | Microangiopathic haemolysis with atypical features | Below 10% confirms TTP |
| Antiplatelet antibodies | Nobody | Not useful for diagnosis |
Obtain a reticulocyte count, blood film, liver tests and HIV, hepatitis C and hepatitis B screening when ITP is suspected.
Moderate RecLow EvidenceASH 2013ICR 2019Add antiphospholipid antibodies, ANA, thyroid tests or H. pylori testing only when the history or examination suggests them.
Conditional RecLow EvidenceASH 2013Do not order antiplatelet antibody tests to diagnose gestational thrombocytopenia or ITP. Practice impact: remove them from antenatal thrombocytopenia order sets.
AgainstModerate EvidenceACOG PB 207ICR 2019Avoid routine bone marrow examination for isolated thrombocytopenia in pregnancy; reserve it for other cytopenias, abnormal cells on the film or failure of ITP therapy.
AgainstLow EvidenceASH Educ 2022ICR 2019Check coagulation studies when the count is below 100 × 10⁹/L, when bleeding occurs, or when liver dysfunction or abruption is suspected.
Moderate RecLow EvidenceACOG PB 222Could This Be a Thrombotic Microangiopathy?
Schistocytes and a raised LDH alongside thrombocytopenia in pregnancy define a thrombotic microangiopathy. Preeclampsia with severe features and HELLP syndrome are by far the most common cause in the late second and third trimesters, but pregnancy is also a trigger for TTP and complement-mediated TMA — and these are not cured by delivery.3,11 Congenital TTP presents almost as often as immune TTP when the first episode occurs in pregnancy.3,13
Which Microangiopathy Is This?
This discriminator is Medaptly’s synthesis of ASH Education Program guidance and the international working group report; overlap is common, so involve haematology early.
| Condition | Clue That Should Raise It | Decisive Finding | Does Birth Resolve It? | First Action |
|---|---|---|---|---|
| Preeclampsia with severe features or HELLP | After 20 weeks, hypertension, RUQ pain | High LDH and AST, falling platelets | Usually, over days | Magnesium, blood pressure control, plan birth |
| Acute fatty liver of pregnancy | Vomiting, confusion, hypoglycaemia | Prolonged PT, low fibrinogen, high bilirubin and ammonia | Yes, with supportive care | Correct coagulopathy and glucose; deliver |
| TTP | Onset before 20 weeks possible, neurological or cardiac signs, platelets often below 30 × 10⁹/L | ADAMTS13 below 10% | No | Plasma exchange without waiting for the assay |
| Complement-mediated TMA | Severe kidney injury, often postpartum or worsening after birth | ADAMTS13 preserved, TMA persists | No | Nephrology and haematology; complement inhibition |
| DIC | Abruption, haemorrhage, amniotic fluid embolism, sepsis | Low fibrinogen, prolonged PT | Only if the trigger is removed | Treat the cause; replace fibrinogen |
Send ADAMTS13 activity when the microangiopathy has features atypical for HELLP — onset before 20 weeks, prominent neurological or cardiac involvement, platelets below 30 × 10⁹/L or severe kidney injury. Practice impact: draw the sample before any plasma is given.
Strong RecLow EvidenceASH Educ 2022Fakhouri 2020Start plasma exchange without waiting for the ADAMTS13 result when TTP is clinically likely.
Strong RecLow EvidenceASH Educ 2022ISTH 2020Evaluate for complement-mediated TMA when severe kidney injury dominates, or when the microangiopathy begins or worsens after birth.
Moderate RecLow EvidenceFakhouri 2020Reassess the diagnosis when HELLP-type results keep worsening after delivery; continued deterioration beyond about day 4 postpartum should prompt a search for TTP or complement-mediated TMA.
Strong RecLow EvidenceACOG PB 222Do not deliver solely to treat TTP or complement-mediated TMA that is responding to therapy.
Moderate RecLow EvidenceASH Educ 2022Avoid routine caplacizumab in pregnancy, for which safety data are insufficient, and weigh rituximab against neonatal risk.
Conditional RecLow EvidenceASH Educ 2022Is It Gestational Thrombocytopenia or ITP?
No test confirms either diagnosis, so the distinction between the two commonest causes of thrombocytopenia in pregnancy rests on history, timing, depth and trajectory.1,5 Both can coexist: a woman with known ITP can develop gestational thrombocytopenia on top, and more than half of women with pre-existing ITP in one cohort fell below 80 × 10⁹/L during pregnancy.2,3
Suspect ITP when there is a previous diagnosis, first-trimester onset, a count below 70 × 10⁹/L, bleeding symptoms, or a progressive fall.
Moderate RecLow EvidenceACOG PB 207ASH 2013Manage a count below 50 × 10⁹/L without another explanation as presumed ITP while the workup continues.
Conditional RecLow EvidenceASH Educ 2025Counsel women with gestational thrombocytopenia that it does not harm them or the baby and needs no specialised care.
Strong RecModerate EvidenceACOG PB 207ASH 2013Confirm gestational thrombocytopenia retrospectively by a normal postpartum count; refer when thrombocytopenia persists beyond about 6 weeks after birth.
Moderate RecLow EvidenceASH 2013Clinical Decision Pathway
A question-based route through thrombocytopenia in pregnancy from the first abnormal result to the birth plan.
When Does ITP in Pregnancy Need Treatment?
ITP is the main cause of thrombocytopenia in pregnancy that needs drug treatment, yet only about one-third of women with known ITP require it.16 In a cohort of 149 pregnancies, corticosteroids and IVIG achieved similar response rates (38% and 39%), both lower than those seen outside pregnancy.15
Treat ITP in pregnancy when there is bleeding, when the count falls below 30 × 10⁹/L, or to reach a target for a planned procedure. Practice impact: an asymptomatic count of 30 × 10⁹/L or more before about 36 weeks is monitored, not treated.
Strong RecLow EvidenceACOG PB 207ICR 2019Start oral prednisone as first-line therapy; consider a lower starting dose of 10–20 mg daily when thrombocytopenia is not severe and birth is not imminent.
Moderate RecLow EvidenceACOG PB 207Gernsheimer 2013Prescribe IVIG when a rapid rise is needed, corticosteroids fail, or side effects are unacceptable.
Moderate RecLow EvidenceACOG PB 207ICR 2019Reconsider the diagnosis when there is no response, even transiently, to IVIG — especially without a history of ITP outside pregnancy.
Moderate RecLow EvidenceASH Educ 2022Consider a thrombopoietin receptor agonist off-label only for refractory disease, after a documented risk–benefit discussion.17
Conditional RecLow EvidenceASH Educ 2022Michel 2020Consider rituximab or azathioprine for refractory ITP, counselling on neonatal B-cell depletion with rituximab.
Conditional RecLow EvidenceASH Educ 2025Consider splenectomy for refractory disease, optimally in the second trimester.
Conditional RecLow EvidenceACOG PB 207Do not use fostamatinib in pregnancy or during lactation.
AgainstLow EvidenceASH Educ 2022ITP Therapies in Pregnancy: Role, Dose and Trade-Offs
Doses below are those reported in ASH Education Program reviews; starting dose, tapering, infusion rates and product choice follow local haematology protocols.
| Therapy | Role in Pregnancy | Usual Dose | Maternal and Fetal Concerns | Practical Note |
|---|---|---|---|---|
| Prednisone | First line | 0.25–1 mg/kg daily; some start at 10–20 mg | Gestational diabetes, hypertension, mood change; cleft risk with early exposure | Screen glucose; taper to the lowest effective dose |
| IVIG | First line when speed matters | 1 g/kg; total 0.5–2 g/kg over 1–5 days, maximum 1 g/kg per 24 h | Headache, haemolysis, thrombosis | Effect is transient; time it to the planned birth |
| Platelet transfusion | Bleeding or pre-procedure | Per local protocol | Rise is short-lived in ITP | Give alongside IVIG or corticosteroids |
| Romiplostim or eltrombopag | Refractory disease, off-label | Romiplostim 1–10 µg/kg weekly; eltrombopag 25–75 mg daily | Limited data; likely placental transfer; neonatal thrombocytopenia reported | Responses in about two-thirds of a small series |
| Rituximab | Refractory disease | 375 mg/m² weekly for 4 weeks | Infection, hepatitis B reactivation; neonatal B-cell depletion | Screen for hepatitis B; inform neonatal team |
| Azathioprine | Refractory, slow-acting | 1–2 mg/kg daily, maximum 150 mg | Experience from other pregnancy indications | Too slow for an imminent birth |
| Splenectomy | Refractory disease | Not applicable | Surgical risk rises later in pregnancy | Second trimester; vaccinate beforehand |
What Platelet Count Is Enough for Birth?
For any thrombocytopenia in pregnancy, platelet thresholds for birth rest on consensus and cohort data rather than trials.4,14 The ASH Education Program summary of targets is 50 × 10⁹/L or more for cesarean and 70 × 10⁹/L or more for neuraxial anaesthesia, recognising the limited evidence.4
Raise the count to 50 × 10⁹/L or more before cesarean or other major surgery, using platelet transfusion when needed.
Strong RecLow EvidenceACOG PB 207ASH Educ 2025Proceed with neuraxial anaesthesia when the count is 70 × 10⁹/L or more and stable, with normal platelet function, no other coagulopathy and no antiplatelet or anticoagulant therapy. Practice impact: do not default to general anaesthesia at counts of 70–99 × 10⁹/L.
Moderate RecLow EvidenceSOAP 2021ACOG PB 207Obtain a recent platelet count before neuraxial placement and catheter removal, timed to the trajectory — within about 6 hours when counts are changing quickly, as in HELLP.
Strong RecLow EvidenceSOAP 2021Decide the mode of birth on obstetric indications, not on thrombocytopenia in pregnancy alone. Practice impact: do not book cesarean for ITP alone.
Strong RecModerate EvidenceACOG PB 207Do not perform fetal scalp sampling or cordocentesis to measure fetal platelets in maternal ITP.
AgainstLow EvidenceACOG PB 207Avoid fetal scalp electrodes, vacuum extraction and rotational forceps when fetal thrombocytopenia is possible.
Conditional RecLow EvidenceGernsheimer 2013Arrange an antenatal anaesthesia review for any count below 100 × 10⁹/L so neuraxial options are planned before labour.
Moderate RecLow EvidenceSOAP 2021Working Platelet Targets Around Birth
| Situation | Working Threshold (× 10⁹/L) | Basis | If Below Threshold |
|---|---|---|---|
| Antepartum, no bleeding, no procedure | 30 or more | Expert opinion | Treat ITP; look for the cause |
| Vaginal birth | About 30–50 | Expert opinion | Treat and have platelets available |
| Cesarean or major surgery | 50 or more | Consensus | IVIG with or without steroids; transfuse at surgery |
| Neuraxial placement | 70 or more, stable | Interdisciplinary consensus with pooled cohort data | Individualise at 50–70, weighing general anaesthesia risks |
| Epidural catheter removal | Same as placement | Consensus | Delay removal and recheck the count |
Who Needs a Different Approach?
Several groups need the standard thrombocytopenia in pregnancy framework adjusted.
Counsel women with chronic ITP before conception on the treatments that may be needed, and advise delaying pregnancy after recent major bleeding, with refractory severe disease or while on teratogenic therapy.
Moderate RecLow EvidenceASH Educ 2022Cines 2017Evaluate for heparin-induced thrombocytopenia when the count falls by 50% or more 5–14 days after starting heparin.20
Strong RecModerate EvidenceASH HIT 2018Avoid routine platelet monitoring in obstetric patients receiving low-molecular-weight heparin alone, whose HIT risk is very low.
Conditional RecLow EvidenceASH HIT 2018Refer to maternal-fetal medicine when a previous baby had unexplained thrombocytopenia or intracranial haemorrhage, for parental platelet antigen typing, maternal antibody testing and risk-stratified antenatal IVIG with or without prednisone. Practice impact: ask about previous neonatal bruising or bleeding at booking.
Strong RecModerate EvidenceACOG PB 207Bussel 2021Evaluate for type 2B von Willebrand disease with haematology, and avoid desmopressin, which can worsen thrombocytopenia in this subtype.19
Conditional RecLow EvidenceMakhamreh 2021Consider an inherited thrombocytopenia when counts have been lifelong, relatives are affected, platelets are large on the film, or ITP therapy fails.
Conditional RecLow EvidenceASH Educ 2022Monitoring and Follow-Up of Thrombocytopenia in Pregnancy
Follow-up of thrombocytopenia in pregnancy depends on the cause. Gestational thrombocytopenia needs little more than a count at birth and a postpartum check; ITP needs planning for the birth and the newborn. Neonatal thrombocytopenia below 150 × 10⁹/L affects about 10–15% of babies born to mothers with ITP, and intracranial haemorrhage is rare.22,23
Recheck the count in gestational thrombocytopenia with routine third-trimester bloods and on admission for birth, without specialist-led serial testing.
Moderate RecLow EvidenceACOG PB 207Monitor ITP counts more often as term approaches, with a planning review at 34–36 weeks.
Moderate RecLow EvidenceSankaran 2011Document a multidisciplinary birth plan covering platelet targets, neuraxial options, blood product availability and neonatal care.
Strong RecLow EvidenceASH Educ 2025Obtain a neonatal platelet count at birth for babies of mothers with ITP, and repeat it over the next days because the nadir typically occurs 2–5 days after birth. Practice impact: a normal cord count does not end neonatal surveillance.
Strong RecLow EvidenceACOG PB 207Repeat the maternal count postpartum to confirm resolution of gestational thrombocytopenia and to detect postpartum ITP relapse.
Moderate RecLow EvidenceASH 2013Arrange haematology follow-up after TTP or complement-mediated TMA to plan monitoring and prophylaxis for future pregnancies.
Moderate RecLow EvidenceFakhouri 2020| What to Check | For Whom | When | Act If |
|---|---|---|---|
| Maternal platelet count | Gestational thrombocytopenia | Third trimester and admission for birth | Below 100 × 10⁹/L or falling |
| Maternal count and bleeding review | ITP | More often near term; plan at 34–36 weeks | Below 30 × 10⁹/L, bleeding, or below birth targets |
| Neonatal platelet count | Babies of mothers with ITP | At birth and over days 2–5 | Severe thrombocytopenia; consider cranial imaging per neonatal protocol |
| Postpartum maternal count | All with thrombocytopenia in pregnancy | Postpartum visit | Persisting beyond about 6 weeks |
| Future-pregnancy plan | ITP, TTP, complement-mediated TMA, FNAIT | Before discharge or postpartum visit | No documented preconception plan |
Evidence in Context
Where guidance on thrombocytopenia in pregnancy agrees, differs, and what the data add.
The Gestational Thrombocytopenia Floor▾
ACOG frames 100–149 × 10⁹/L in asymptomatic women as usually gestational, while the ASH pocket guide uses 70 × 10⁹/L as the level below which another cause should be sought. Reese’s population data support investigating below 100 × 10⁹/L, since only 1% of uncomplicated pregnancies reach that level.
Where the ASH Advice Comes From▾
The 2019 ASH ITP guideline does not provide pregnancy-specific recommendations,9 so ASH-affiliated advice on thrombocytopenia in pregnancy rests on the 2013 pocket guide, the 2019 international consensus and ASH Education Program reviews — all largely consensus-based.
Corticosteroids Versus IVIG▾
The largest comparative cohort found no difference in response between the two, so the choice rests on speed, side effects, cost and patient preference rather than efficacy.15
Neuraxial Thresholds▾
The SOAP consensus, endorsed by obstetric and anaesthesia bodies, moved practice from a fixed 100 × 10⁹/L rule toward a trend-based 70 × 10⁹/L threshold.14
Evidence Gaps
- No randomised trial compares treatment thresholds or first-line agents for ITP-related thrombocytopenia in pregnancy.
- Platelet targets for vaginal and cesarean birth remain consensus-based.
- Neuraxial safety data at 50–70 × 10⁹/L are sparse.
- Thrombopoietin receptor agonist safety in pregnancy rests on small retrospective series.
- Rapid ADAMTS13 testing is not widely available, and bedside TTP prediction scores have limited validation in pregnancy.
- The best antenatal IVIG regimen for fetal and neonatal alloimmune thrombocytopenia, and screening for it, remain debated.
References
- 1.American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 207: Thrombocytopenia in pregnancy. Obstet Gynecol. 2019;133(3):e181-e193. https://doi.org/10.1097/AOG.0000000000003100
- 2.Reese JA, Peck JD, Deschamps DR, et al. Platelet counts during pregnancy. N Engl J Med. 2018;379(1):32-43. https://doi.org/10.1056/NEJMoa1802897
- 3.Pishko AM, Marshall AL. Thrombocytopenia in pregnancy. Hematology Am Soc Hematol Educ Program. 2022;2022(1):303-311. https://doi.org/10.1182/hematology.2022000375
- 4.Matusiak K, Malinowski AK, Arnold DM. A practical approach to immune thrombocytopenia in pregnancy. Hematology Am Soc Hematol Educ Program. 2025;2025(1):503-510. https://doi.org/10.1182/hematology.2025000743
- 5.Gernsheimer T, James AH, Stasi R. How I treat thrombocytopenia in pregnancy. Blood. 2013;121(1):38-47. https://doi.org/10.1182/blood-2012-08-448944
- 6.Cines DB, Levine LD. Thrombocytopenia in pregnancy. Blood. 2017;130(21):2271-2277. https://doi.org/10.1182/blood-2017-05-781971
- 7.Rajasekhar A, Gernsheimer T, Stasi R, James AH. 2013 Clinical practice guide on thrombocytopenia in pregnancy. American Society of Hematology; 2013. https://www.hematology.org/-/media/hematology/files/education/clinicians/guidelines-quality/documents/watermarked-pocket-guides/watermark-thrombocytopenia-pocket-guide.pdf
- 8.Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780-3817. https://doi.org/10.1182/bloodadvances.2019000812
- 9.Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866. https://doi.org/10.1182/bloodadvances.2019000966
- 10.American College of Obstetricians and Gynecologists. Gestational hypertension and preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020;135(6):e237-e260. https://doi.org/10.1097/AOG.0000000000003891
- 11.Fakhouri F, Scully M, Provôt F, et al. Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood. 2020;136(19):2103-2117. https://doi.org/10.1182/blood.2020005221
- 12.Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2496-2502. https://doi.org/10.1111/jth.15010
- 13.Moatti-Cohen M, Garrec C, Wolf M, et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood. 2012;119(24):5888-5897. https://doi.org/10.1182/blood-2012-02-408914
- 14.Bauer ME, Arendt K, Beilin Y, et al. The Society for Obstetric Anesthesia and Perinatology interdisciplinary consensus statement on neuraxial procedures in obstetric patients with thrombocytopenia. Anesth Analg. 2021;132(6):1531-1544. https://doi.org/10.1213/ANE.0000000000005355
- 15.Sun D, Shehata N, Ye XY, et al. Corticosteroids compared with intravenous immunoglobulin for the treatment of immune thrombocytopenia in pregnancy. Blood. 2016;128(10):1329-1335. https://doi.org/10.1182/blood-2016-04-710285
- 16.Webert KE, Mittal R, Sigouin C, Heddle NM, Kelton JG. A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenic purpura. Blood. 2003;102(13):4306-4311. https://doi.org/10.1182/blood-2002-10-3317
- 17.Michel M, Ruggeri M, Gonzalez-Lopez TJ, et al. Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study. Blood. 2020;136(26):3056-3061. https://doi.org/10.1182/blood.2020007594
- 18.Bussel JB, Vander Haar EL, Berkowitz RL. New developments in fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol. 2021;225(2):120-127. https://doi.org/10.1016/j.ajog.2021.04.211
- 19.Makhamreh MM, Russo ML, Karl T, et al. Type 2B von Willebrand disease in pregnancy: a systematic literature review. Semin Thromb Hemost. 2021;47(2):201-216. https://doi.org/10.1055/s-0041-1723799
- 20.Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360-3392. https://doi.org/10.1182/bloodadvances.2018024489
- 21.WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105-2116. https://doi.org/10.1016/S0140-6736(17)30638-4
- 22.Fujimura K, Harada Y, Fujimoto T, et al. Nationwide study of idiopathic thrombocytopenic purpura in pregnant women and the clinical influence on neonates. Int J Hematol. 2002;75(4):426-433. https://doi.org/10.1007/BF02982137
- 23.Sankaran S, Robinson SE. Immune thrombocytopenia and pregnancy. Obstet Med. 2011;4(4):140-146. https://doi.org/10.1258/om.2011.110025
How to Read the Evidence Tags
Every recommendation carries a strength tag and an evidence tag — Medaptly’s own simplified reading of the underlying guidance, not a reproduction of any source body’s grading system.
| Strength Tag | What It Means |
|---|---|
| Strong Rec | High-quality evidence broadly supports this action |
| Moderate Rec | The weight of evidence favours this action |
| Conditional Rec | The benefit is less certain — individualise |
| Against | Evidence points to no benefit or potential harm |
| Evidence Tag | What It Means |
|---|---|
| High Evidence | Multiple well-designed trials or high-quality meta-analyses |
| Moderate Evidence | A single trial or large observational dataset |
| Low Evidence | Expert consensus or small studies |